Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

A Breakthrough Therapy Developed for Investigational Prenatal Treatment ER-004 a Rare Genetic Condition

ER-004, a breakthrough therapy for the prenatal treatment of XLHED, a life-threatening rare genetic condition was developed by EspeRare.

Breakthrough Designation was obtained by the promising results from three XLHED subjects with a course of ER-004 intra-amniotic injections during the third trimester of pregnancy.Hence results obtained from this prenatal treatment have a profound and life-changing effect on these infants.

Rare diseases such as XLHED often don't receive much attention and research investments that patients and their families deserve.This breakthrough therapy approach has the potential to fundamentally change the lives of patients and may also pave the way for other prenatal treatments to correct genetic diseases before birth.

US FDA grants Breakthrough Therapy Designation for Investigational Prenatal Treatment ER-004 in X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED)protein replacement therapy for the treatment for the prenatal treatment of XLHED, a life-threatening rare genetic condition.

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinRehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024